The formation of new microvasculature is essential for a tumor mass to grow. Vascular targeting agents (VTAs),
including anti-angiogenic drugs and vascular disrupting agents, aim to either inhibit new vasculature growth or destroy
existing vasculature, respectively. Because the mechanisms for anti-angiogenic drugs and vascular disrupting agents are
complementary, analysis of these drugs used together is under investigation for the enhanced treatment of tumors in
comparison to each treatment alone. The preclinical evaluation of the effects of VTAs on tumor growth in small animal
models is vital for the development of effective drugs for clinical use. In vivo hyperspectral imaging microscopy of
hemoglobin saturation has been used previously to investigate the efficacy of VTAs through analysis of tumor
microvessel oxygenation after drug administration. Combining this imaging modality with first-pass fluorescence
angiographic imaging can give additional important information about the vessel morphology and blood flow changes
that occur after VTA treatment, thus elucidating the relationship between microvessel structure changes and
oxygenation. In this study, we report the combined use of hyperspectral and first pass fluorescence angiographic
imaging to examine the relationship between vessel morphology and oxygenation of human prostate cancer tumors in
mice following treatment with vascular disrupting agents, OXi4503, and anti-VEGF angiogenesis inhibitor, cediranib.
Imaging of the tumors is completed before treatment as well as in the days following treatment.